Silence Therapeutics PLC Two further US patents to be granted (9797N)
August 15 2017 - 2:00AM
UK Regulatory
TIDMSLN
RNS Number : 9797N
Silence Therapeutics PLC
15 August 2017
Two further US patents to be granted
15 August 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that the US Patent and Trade Mark Office
has issued a notice of allowance for US patent applications
15/589,968 and 15/594,349.
Silence has made the relevant payment of grant fees and normal
practice is that the granted patents will now be issued by the US
Patent and Trade Mark Office. The allowed claims of both patent
applications provide Silence with further protection for its
innovative chemical modification technology in the US. Silence
believes these allowed claims are relevant to third party
medicines in ongoing clinical trials.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics,
commented:
"The two additional patent applications that have been allowed
for grant by the US Patent and Trade Mark Office provide further
protection for our US patent estate. With the grant of these, and
other recently allowed US patent applications, we will have nine
granted US patents, one US patent application, three granted
European patents and four European patent applications encompassing
our chemical modification technology. We continue to believe that
several third party late--stage clinical RNAi candidates require
licences under our patent portfolio and that such licences could
have a material financial effect on Silence."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Ali Mortazavi, Chief Executive Officer 6900
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418
James Steel/Oliver Jackson 8900
Media Enquiries: Tel: +44 (0) 20 3727
FTI Consulting 1000
Simon Conway/Brett Pollard/Stephanie Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDDGDICXBBGRS
(END) Dow Jones Newswires
August 15, 2017 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024